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Ryanodine Receptors (RyRs) are huge Ca2+ release
channels in the endoplasmic reticulum membrane
and form targets for phosphorylation and disease
mutations. We present crystal structures of a domain
in three RyR isoforms, containing the Ser2843 (RyR1)
and Ser2808/Ser2814 (RyR2) phosphorylation sites.
The RyR1 domain is the target for 11 disease muta-
tions. Several of these are clustered near the phos-
phorylation sites, suggesting that phosphorylation
and disease mutations may affect the same inter-
face. The L2867G mutation causes a drastic thermal
destabilization and aggregation at room tempera-
ture. Crystal structures for other disease mutants
show that they affect surface properties and intrado-
main salt bridges. In vitro phosphorylation experi-
ments show that up to five residues in one long
loop of RyR2 can be phosphorylated by PKA or
CaMKII. Docking into cryo-electron microscopy
maps suggests a putative location in the clamp
region, implying that mutations and phosphorylation
may affect the allosteric motions within this area.
INTRODUCTION
Ryanodine receptors (RyRs) are ion channels that mediate the
release of Ca2+ from the endoplasmic reticulum (ER). They are
involved in many physiological events that depend on Ca2+ as
a second messenger, which includes excitation-contraction
(EC) coupling in various types of muscle. In mammalian organ-
isms, three different isoforms have been identified (RyR1–3)
(Hakamata et al., 1992; Otsu et al., 1990; Takeshima et al.,
1989), sharing both sequence and structural homology. RyR1
is mainly found in skeletal muscle, whereas RyR2 is the isoform
that predominates in cardiac myocytes.
Mutations in RyRs have been linked to severe disease pheno-
types, reflecting their importance in the tight regulation of Ca2+
release during muscle contraction (Betzenhauser and Marks,
2010; Priori and Chen, 2011). More than 200 mutations have
been identified in RyR1, and they are associated with malignant
hyperthermia (Gillard et al., 1991), as well as central core disease
and related conditions (Jungbluth et al., 2003). In the cardiac iso-Structure 20, 1form, more than 150 mutations have been linked to catechol-
aminergic polymorphic ventricular tachycardia (CPVT) (Priori
et al., 2001), arrhythmogenic right ventricular dysplasia type 2
(ARVD2), and idiopathic ventricular fibrillation (IVF) (Priori et al.,
2002). Most mutations found so far still cluster in three ‘‘hot
spots,’’ although several mutations have been found outside of
these three regions.
RyRs form homotetrameric assemblies with molecular
weights exceeding 2 MDa. Several high- and low-resolution
studies have shed light on their structure (Kimlicka and Van
Petegem, 2011). Cryo-electron microscopy (cryo-EM) studies
reveal a mushroomlike shape, with a large cytoplasmic cap
and a smaller transmembrane stalk (Ludtke et al., 2005; Samso´
et al., 2005, 2009). The cytoplasmic portion, accounting for
>80% of the mass, contains many solvent channels that maxi-
mize the exposed surface area to allow binding of many proteins
and small molecule ligands. A systematic study comparing
the open and closed states has shown that many regions in
the cytoplasmic portion undergo substantial movements,
demonstrating that the RyR is an allosteric protein (Orlova
et al., 1996; Samso´ et al., 2009; Serysheva et al., 1999; Sharma
et al., 2000) and that regulatory proteins and ligands may affect
channel opening by interfering with the allosteric motions. High-
resolution studies have revealed the structures of domains in
the N-terminal disease hot spot of both RyR1 and RyR2 (Amador
et al., 2009; Lobo et al., 2011; Lobo and Van Petegem, 2009;
Tung et al., 2010). This hot spot is built up by three domains
(A, B, and C) that interact with one another through a mostly
hydrophilic interface (Tung et al., 2010). It is located at the central
rim, and four N-terminal disease hot spots in a RyR tetramer
interact with one another, forming a cytoplasmic vestibule.
RyRs are under the control of both kinases and phosphatases.
The cAMP-activated kinase (PKA) targets several cytoplasmic
proteins, and at least two residues per RyR subunit (S2843 in
human RyR1; S2030 and S2808 in human RyR2) can be phos-
phorylated by PKA. S2808 was found to be hyperphosphory-
lated by PKA in heart failure, leading to the dissociation of
FKBP12.6 (Marx et al., 2000; Wehrens et al., 2006), but this
has not been confirmed in other studies (George et al., 2003;
Jiang et al., 2002; Zhang et al., 2012). Other reports found
instead that S2030 is the major PKA target residue in RyR2
(Xiao et al., 2005, 2006). CaMKII has been found to phosphory-
late S2843 on RyR1 (Suko et al., 1993) and S2808 in RyR2
(Witcher et al., 1991; Xiao et al., 2005), but also seems to have
a unique phosphorylation site in RyR2 (S2814) (Wehrens et al.,
2004). It can increase the open probability and Ca2+ sensitivity201–1211, July 3, 2012 ª2012 Elsevier Ltd All rights reserved 1201
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Figure 1. Overall Structure of the Phosphorylation Domain
(A–C) Shown are cartoon representations of the phosphorylation domain in
RyR1 (A), RyR2 (B), and the corresponding domain in RyR3 (C). The flexible
phosphorylation loop is indicated by dotted lines, and the positions of the well-
studied phosphorylation sites S2843 (RyR1) and S2808/S2814 (RyR2: human
numbering) are indicated. Secondary structure elements are labeled for the
RyR1 domain. See also Figure S1 and Table 1.
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Structure of the RYR Phosphorylation Hot Spotof the channel (Wehrens et al., 2004), and has also been shown
to contribute to cardiac arrhythmia and contractile dysfunction
(Ai et al., 2005; Kushnir et al., 2010). A recent study on mouse
tissue has identified multiple additional phosphorylation sites in
this area of RyR2 (Huttlin et al., 2010), turning the region into
a phosphorylation hot spot.
Here, we present crystal structures for the RyR1 and RyR2
domains containing these phosphorylation sites, as well as
the corresponding RyR3 domain. We probe the effect of RyR1
disease mutations on the structure and stability and locate
the positions of up to eight different phosphorylation sites.
Docking into cryo-EM maps suggests a putative location in
the clamp region. This study represents the first report, to our
knowledge, of crystal structures of a domain in the central
region of RyRs.
RESULTS
Overall Structure
We solved the crystal structures of a domain that is the target for
phosphorylation in the central region of rabbit RyR1 (2734–2940)
and mouse RyR2 (2699–2904), as well as the corresponding
domain in human RyR3 (2597–2800), at 1.65–1.95A˚ (Figure 1
and Table 1; Figure S1A available online). The RyR2 domain
was solved via multiple anomalous dispersion using selenome-
thionine-substituted protein, whereas the RyR1 and RyR3
domains were solved by using the RyR2 domain as a molecular
replacement search model. The domains encode two repeats,
also known as ‘‘RyR domains,’’ which are also present in two
tandem pairs closer to the RyR N terminus (Hamilton and Sery-
sheva, 2009). In both RyR1 and RyR2, the phosphorylation
domain consists of a two-fold symmetrical structure, consistent
with the two repeats. Each half is built up by two a helices, one
or more short 310 helices, and a C-terminal b strand (a1, a2,
and b for the first half; a1’, a2’, and b’ for the second half) (Fig-
ure 1). The two repeats are separated by a long loop, for which1202 Structure 20, 1201–1211, July 3, 2012 ª2012 Elsevier Ltd All riga significant portion is flexible. This linker contains the previously
identified phosphorylation targets S2843 (RyR1) and S2808/
S2814 (RyR2, human numbering). We will refer to the entire
domain as the ‘‘phosphorylation domain,’’ and to the loop as
the ‘‘phosphorylation loop.’’
The two halves interact with one another, with the b strands
forming a short antiparallel b sheet. The two-fold symmetry is
particularly striking, because a 180 rotation yields a very good
superposition on itself (Figure 2). The overall symmetry is less
conserved in RyR3, where the flexible linker is partially replaced
by an additional alpha helix a3 (Figure 1C). With the exception of
this extra helix, all three domains superpose very well (Fig-
ure S1B), with RMSD values of 1.48 A˚ (RyR1 versus RyR2, 168
Ca atoms) and 1.50 A˚ (RyR1 versus RyR3, 177 Ca atoms).
Searches with the DALI server (ekhidna.biocenter.helsinki.fi/
dali_server/) indicate that the domains display only very distant
structural homology with other proteins, such as ferric uptake
regulators. However, several prokaryotes encode similar
domains, corresponding to either single or tandem repeats. A
crystal structure of a small 100 aa domain from Bacteroides
thetaiotaomicron VPI-5482 shows that it dimerizes to form
a similar arrangement (Protein Data Bank [PDB] accession
code 3NRT), and suggests that the repeats in RyRs may have
a prokaryotic origin (Mackrill, 2012).
Disease Mutations
Both RyR1 and RyR2 are targets for many disease mutations.
None can be mapped on the RyR2 phosphorylation domain,
but at least 11 mutations are located on the RyR1 structure (Fig-
ure 3; Table S1). Interestingly, their distribution is not random,
and they can be divided into three groups.
Group 1 contains seven mutations that are located on the
same face of the domain, which also includes the S2843 phos-
phorylation target. R2840W and S2843P are found within the
phosphorylation loop, with S2843P directly abolishing the target
site. E2764K is part of helix a1 and is pointing toward the phos-
phorylation loop. Four additional mutations (S2776M, S2776F,
L2785V, and T2787S) are clustered immediately C-terminal to
a1 and seem to form a local ‘‘micro-hot spot,’’ because the three
affected amino acids are all in Van Der Waals contact. The clus-
tering of all seven mutations near the S2843 phosphorylation
target suggests that either phosphorylation or mutations in this
area may affect the same interaction with a neighboring domain
or auxiliary subunit.
Group 2 contains three mutants on the surface opposite to
group 1: R2939S and R2939K affect the very C-terminal residue
in the structure, whereas E2880K is located on helix a1’. Finally,
group 3 consists of a single mutant that abolishes a buried
hydrophobic side chain (L2867G). This mutation is thus ex-
pected to cause significant destabilization and may cause mis-
folding. Overall, the distribution of the mutations in groups 1
and 2 suggests that this domain is involved in at least two inter-
faces that are functionally important.
Thermal Melts
One possible mechanism for a disease mutation is that it affects
the overall stability of a protein or even causes misfolding. We
therefore prepared several versions of the RyR1 phosphorylation
domain, corresponding to nine different disease mutations, andhts reserved
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three wild-type domains have a very similar overall thermal
stability, with melting temperatures of 48–50C (Figure 4). Most
RyR1 mutations cause a mild destabilization or have no sig-
nificant effect. The L2867G mutation, however, has a melting
temperature that is 13C lower (37.0C ± 0.9C). This mutant
domain also aggregates and precipitates readily at room
temperature. A size exclusion chromatogram at 4C shows
that the mutant still behaves as a monomer and does not
aggregate, indicating that it is still able to fold properly at lower
temperatures (Figure S2). The L2867 side chain is involved in
hydrophobic contacts with L2871 and L2927 (Figure 5A). A
disruption of this hydrophobic core thus explains the decreased
stability and may result in structural rearrangements.
Crystal Structures of Mutants
In order to check whether the mutations only affect the local
structure or can also create longer-range deviations, we solved
the crystal structures of several disease mutants. The mutation
that affected the thermal stability the most, L2867G, failed to
crystallize, suggesting that there are indeed larger structural
changes beyond a side chain truncation.
The E2764K mutant was solved at 2.2 A˚. The E2764 residue is
located on helix a1, and together with the neighboring E2760, it
forms a negatively charged patch on the surface. The mutation
to a lysine residue only creates minor shifts in the neighboring
residues, and the main effect of the mutation is therefore to
alter the charge properties of the surface (Figure 5B).
The S2776M mutant was solved at 1.6 A˚. S2776 is located on
a loop connecting helices a1 and a2 and is part of a local hot
spot containing four disease mutations (Figure 3). The S2776
hydroxyl group forms a hydrogen bond with the main chain of
the neighboring Y2777 and thus seems involved in maintaining
the local structure of this loop (Figure 5C). Mutation to a methio-
nine residue disrupts this hydrogen bond, and some rearrange-
ment of the loop is observed. The methionine residue increases
the hydrophobicity of this region and causes a distinct protrusion
compared to the wild-type surface.
The R2939S mutant was solved at 2.2 A˚. As the C-terminal
residue of the domain, the R2939 side chain is involved in
multiple interactions (Figure 5D). This includes a salt bridge
and hydrogen bonds with E2870 and Q2877, both located on
helix a1’. It also forms hydrogen bonds with an ordered water
molecule that is involved in a hydrogen bond network. In addi-
tion, the R2939 side chain makes Van der Waals contacts with
the buried residues M2874 and W2821. Mutation to a serine
residue disrupts all of these interactions, resulting in increased
flexibility, because the Q2877 side chain now adopts two
conformations.
Finally, although the phosphorylation loop was entirely flex-
ible in the wild-type structure, we wondered whether particular
mutations in this loop (S2840W and S2843P) could induce
structure or interactions with the remainder of the domain.
However, in both cases the loop remained flexible, and no
electron density was observed for this region. In addition, the
S2843D mutation, which would mimic a permanently phos-
phorylated residue, still resulted in a completely flexible loop.
Similarly, the S2808D mutation in the RyR2 phosphorylation
domain yielded an identical structure.Structure 20, 1The Phosphorylation Domain Does Not Interact with
Calmodulin or FKBPs
RyRs are regulated by Calmodulin (CaM), and several peptides
have been predicted or shown to interact with CaM in vitro.
The first predictions included peptide sequences that are
located within the phosphorylation domain (Otsu et al., 1990;
Zorzato et al., 1990), and overlay assays have shown that CaM
can interact weakly with peptides that are part of the domain
(Chen and MacLennan, 1994). The CaM target database
(http://calcium.uhnres.utoronto.ca) also predicts up to three
sequences in the phosphorylation domain that can interact
with CaM (Figure 6A). Within the folded domain, however, these
segments are only partially accessible (Figure S3A). Using ITC,
we failed to detect any interaction between Ca2+/CaM and the
RyR2 phosphorylation domain (Figure S3B).
FKBPs bind and stabilize the RyR closed state. Some studies
have concluded that phosphorylation of S2808 causes dissocia-
tion of FKBP12.6 (Marx et al., 2000).We therefore testedwhether
the RyR2 phosphorylation domain could contribute to the
binding. However, as with CaM, no significant interaction could
be detected using ITC (Figure S3C), so a direct contribution
from this domain can only be minor.
RyR2 Phosphorylation Specificity
Within the RyR2 phosphorylation domain, two serine residues
have received extensive attention as targets for kinases. Using
the human RyR2 numbering, this includes S2808 (PKA, PKG,
and CaMKII) (Marx et al., 2000; Witcher et al., 1991; Xiao et al.,
2006) and S2814 (CaMKII) (Wehrens et al., 2004). PKA has
been shown to be associated with RyR2 via its anchoring
protein mAKAP, ensuring a high local concentration of PKA
next to one of its target proteins (Marx et al., 2001). In theory,
the specificity of PKA for its RyR2 target serines could be
dictated by the overall 3D structure of intact RYR2, by hiding
individual segments or by altering some small portions of the
structure to present a better substrate. We therefore decided
to phosphorylate the RyR2 domain with both PKA and CaMKII
in vitro, trypsinize the protein, and sequence the peptides to
identify the phosphorylated residues via tandem mass spec-
trometry methods. In agreement with previous data, S2808
was found to be phosphorylated by both PKA and CaMKII, and
S2814 was phosphorylated by CaMKII. However, multiple other
phosphorylation sites were identified (Figure 6 and Table S2). In
particular, PKA phosphorylated four residues in the phosphory-
lation loop, corresponding to human residues S2808, T2810,
S2811, and S2814. In addition, it also phosphorylated S2797,
which is located in a small 310 helix immediately preceding the
phosphorylation loop and is also solvent-exposed in the isolated
domain. Four residues were phosphorylated by CaMKII: S2808,
S2811, S2814, and T2876. The latter residue is the only one not
residing in the phosphorylation loop and is located in a short 310
helix at the opposite surface (Figure 6B).
These data are the result of prolonged exposure to PKA or
CaMKII for a purified domain at high concentration, and by
themselves, they do not imply that the same residues are also
phosphorylated in vivo. However, a recent study has investi-
gated the phospho-proteome of several mouse organs. With
the exception of the T2876 site, all of the sites mentioned above
have also been detected to be phosphorylated in vivo (Huttlin201–1211, July 3, 2012 ª2012 Elsevier Ltd All rights reserved 1203
Table 1. Data Collection and Refinement Statistics
RyR1-R2939S
Data Collection
Space group P21212 C2 P21212 P21212
Cell dimensions
a, b, c (A˚) 56.78, 115.89, 32.21 93.57, 58.54, 47.46 56.24, 114.69, 32.11 56.19, 113.78, 32.15
a, b, g () 90, 90, 90 90, 97.21, 90 90, 90, 90 90, 90, 90
Resolution (A˚) 50.0–1.95 (2.00–1.95)a 50–1.75 (1.80–1.75) 50.0–2.20 (2.28–2.20) 50.0–1.59 (1.64–1.59)
Rsym or Rmerge 0.081 (0.679) 0.035 (0.452) 0.102 (0.301) 0.065 (0.590)
I / sI 17.29 (2.94) 20.30 (3.15) 10.73 (2.61) 12.47 (2.09)
Completeness (%) 100.0 (100.0) 98.1 (99.2) 98.5 (91.3) 95.6 (89.2)
Redundancy 7.2 (7.3) 3.6 (3.6) 4.3 (2.3) 4.0 (3.4)
Refinement
Resolution (A˚) 40.56–1.95 35.35–1.75 28.12–2.20 56.89–1.59
No. of reflections 15,390 24,018 10,258 25,783
Rwork/Rfree 0.190/0.225 0.190/0.220 0.220/0.287 0.196/0.229
No. of atoms
Protein 1,541 1,536 1,489 1,567
Ligand/ion 13 33 24 30
Water 118 209 104 146
B-factors
Protein 28 25 28 21
Ligand/ion 45 41 38 33
Water 37 36 32 35
Rmsds
Bond lengths (A˚) 0.019 0.013 0.002 0.013
Bond angles () 1.54 1.21 0.50 1.10
RyR1-R2939S
Data Collection
Space group P21212
Cell dimensions
a, b, c (A˚) 56.46, 116.42, 32.34
a, b, g () 90, 90, 90
Resolution (A˚) 50.0–2.20 (2.28–2.20)
Rsym or Rmerge 0.062 (0.326)
I / sI 15.04 (1.97)
Completeness (%) 96.2 (77.2)
Redundancy 3.5 (1.7)
Refinement
Resolution (A˚) 116.42–2.19
No. of reflections 10,516
Rwork/Rfree 0.211/0.262
No. of atoms
Protein 1,501
Ligand/ion 18
Water 88
B-factors
Protein 40
Ligand/ion 56
Water 42
Rmsds
Structure
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Table 1. Continued
RyR1-R2939S
Bond lengths (A˚) 0.014
Bond angles () 1.30
SeMet RyR2 (MR) SeMet RyR2 (MAD)
Data Collection
Space group P212121 P212121
Cell dimensions
a, b, c (A˚) 58.90, 88.22, 92.07 58.90, 88.90, 91.80
a, b, g () 90, 90, 90 90, 90, 90
Peak Inflection Remote
Wavelength (A˚) 0.97928 0.97947 0.97740
Resolution (A˚) 50–1.65 (1.69–1.65) 50–2.03 50–2.03 50–2.03
Rsym or Rmerge 0.141 (1.609) 0.179 0.179 0.179
I / sI 9.69 (1.94) 9.05 8.57 8.90
Completeness (%) 100.0 (100.0) 100 100 94.3
Redundancy 10.1 (7.2) 7.8 7.8 7.8
Refinement
Resolution (A˚) 49.05–1.65
No. of reflections 55,490
Rwork/Rfree 0.228/0.250
No. of atoms
Protein 2,666
Ligand/ion 1
Water 329
B-factors
Protein 29
Ligand/ion 56
Water 38
R.m.s deviations
Bond lengths (A˚) 0.016
Bond angles () 1.33
One crystal was used for each data set.
aValues in parentheses are for highest-resolution shell.
Structure
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Given that S2808 and S2814 are established phosphorylation
sites, and hence accessible in full-length RyR2, it is logical that
nearby residues (S2797, T2810, and S2811), within and right
before the same segment, are also accessible. Because T2876
has a completely different location and was not detected in vivo,
it is possible that this residue is not accessible in full-length RyR2
and represents an artifact.
Three additional sites within the RyR2 phosphorylation domain
have also been detected in vivo, including T2781, Y2821, and
S2822 (Figure 6B) (Brill et al., 2009; Huttlin et al., 2010). The
T2781 site so far has only been detected in human RyR2
(Brill et al., 2009). The Y2821 side chain hydroxyl group is not
accessible on the RyR2 domain surface, and therefore the side
chain would have to reorient in order to gain access to a kinase.
This shows that phosphorylation of this residue could induce
a structural change in the domain, trapping the Y2821 side chain
in a rare conformation. In total, the RyR2 domain contains the
locations for at least eight different phosphorylation target sitesStructure 20, 1that have been found in native tissues, and seven of these are
on the same face as the seven group 1 disease mutations.
Location in Full-Length RyR1 Cryo-EM Maps
With several cryo-EM maps available near 10 A˚, we attempted
to locate the domain in the overall 3D structure via unbiased
docking algorithms implemented in ADP_EM (Garzo´n et al.,
2007). Using three different cryo-EM maps—EMDB entries
1606 (Samso´ et al., 2009), 1607 (Samso´ et al., 2009), and 1275
(Ludtke et al., 2005)—the top solution consistently located to
the tip of the clamp region, also known as subregion 10 (Fig-
ure 7A and Figure S4). Previous docking experiments with
domains of the RyR1 N-terminal disease hot spot had shown
that docking of individual domains required the use of a Lapla-
cian filter (Lobo and Van Petegem, 2009; Tung et al., 2010). Inter-
estingly, even without Laplacian filtering, the number 1 ranked
hits fell within the same tip (Figure S4B). In the case of the
RyR1 N-terminal disease hot spot, the correlation coefficient of
the top hit clearly stood out from the next solution down the201–1211, July 3, 2012 ª2012 Elsevier Ltd All rights reserved 1205
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Figure 4. Thermal Melt Analysis
(A) Thermal melting curves using a thermofluor assay for the wild-type RyR1,
RyR2, and RyR3 domains, and the RyR1 L2867G mutant. Each curve is the
average of four measurements.
(B) Melting temperatures for nine different RyR1 mutants. The melting
temperatures correspond to the midpoints of the transitions in (A). Each
column represents the average of four measurements, and the error bars
correspond to standard deviations. See also Figure S2.
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Figure 2. Two-Fold Symmetry
(A) View of the RyR1 phosphorylation domain from the ‘‘top’’ in Figure 1A. Each
half is shown by a different color (red: N-terminal region; yellow: C-terminal
region). The arrow represents a pseudo two-fold symmetry axis.
(B) Superposition of the domain onto itself via a 180 rotation, showing that the
two domains, on the main chain level, are interchangeable. The superposed
version is shown in white.
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Structure of the RYR Phosphorylation Hot Spotranking. In this case, the contrast is lower, resulting in more
ambiguity.
In both the 10.2 A˚ open- and closed-state RyR1 maps, the
top ranked solution shows the phosphorylation loop oriented
toward an internal cavity (Figure 7B, top panel). However,
because of the two-fold symmetry of the domain, there is an
inherent uncertainty for the domain orientation, and, in both
cases, the second ranked solution is the symmetrical equiva-
lent, placing the phosphorylation loop at the periphery of the
structure (Figure 7B, bottom panel). For the 9.6 A˚ map, the
top solution also shows the loop at the periphery. An important
criterion for a correct docking location is that all residues that
have been found to be phosphorylated in vivo are accessible
to kinases and are thus exposed to solvent. Plotting the
RyR2 phosporylation targets on the docked RyR1 domain
structures, both solutions are compatible with this, and there
is therefore an inherent ambiguity in the solution. Interestingly,
most solutions down the ranking are still located in the same tip
region, with slightly altered orientations (Figure S4D). This may
underscore the overall flexibility of this region, resulting in aver-
aged density in the cryo-EM reconstructions and underlying the
lower docking contrast. These docking experiments provideR2939S/R2939K
E2880K
L2867G
E2764K
S2776M / S2776F
S2843P
R2840W
T2787S
L2785V
**
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Face 2
Figure 3. Disease Mutations in the RyR1 Phosphorylation Domain
All mutations are labeled, and the target residues are indicated by black sticks.
The mutations cluster on two faces of the domain (dotted black lines). See also
Table S1.
1206 Structure 20, 1201–1211, July 3, 2012 ª2012 Elsevier Ltd All riga best guess, and the exact position of the phosphorylation
domain will have to be confirmed.
DISCUSSION
We have solved the crystal structures of a domain embedded
within the central regions of all three mammalian RyR isoforms.
The structure displays a pseudo two-fold symmetry that is the
result of tandem repeats that interact with one another through
b strand interactions. Because these repeats are also found in
the sequence closer to the N-terminal half (Hamilton and Sery-
sheva, 2009), the current structures are likely representative of
two additional RyR domains. Serine residues in both RyR1
(S2843) and RyR2 (S2808 and S2814) have previously been
identified as targets for several kinases. They are located in
a flexible loop that connects the repeats.
The RyR1 phosphorylation domain structure harbors the
positions of up to 11 diseasemutations, leading to various condi-
tions, including MH and CCD (Table S1). One mutation (L2867G)hts reserved
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Figure 5. RyR1 Disease Mutant Crystal
Structures
Shown is a superposition of the wild-type RyR1
phosphorylation domain (white) with the mutant
structure (colors). Atoms are color coded, with
nitrogens in blue, oxygens in red, and sulfurs in
yellow. Hydrogen bonds are indicated by dashed
lines.
(A) L2867G mutant (only wild-type structure
shown).
(B) E2764K.
(C) S2776M.
(D) R2939S. The mutated residues in (B)–(D) are
indicated in black.
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Structure of the RYR Phosphorylation Hot Spottargets a buried hydrophobic residue, which causes the domain
to aggregate at room temperature and a 13C destabilizing
shift in thermal melting assays. All other mutations are exposed
at the surface, and seven of them are clustered on the same face
that contains the phosphorylation loop. The remaining three
mutations are on the complete opposite face of the domain.
Crystal structures show that the mutations can affect intrado-
main salt bridges (R2939S) or simply affect the local surface
(S2776M and E2764K). Mutations in the phosphorylation loop
can either directly abolish the S2843 phosphorylation (S2843P)
site or remove a positive charge (R2840W). The removal of
a positive charge may have the same effect as the addition of
a negative charge by phosphorylation.
The effect of phosphorylation on RyR function is a controver-
sial topic. One initial study suggested that S2808 is hyper-
phosphorylated in heart failure and that this leads to the dissoci-
ation of FKBP12.6 (Marx et al., 2000). However, several groups
have failed to reproduce the dissociation, and it is likely that
differences in the preparations underlie the discrepancies.
FKBP12.6 has been suggested to bind to an isoleucyl-prolyl
motif in RyR2 (aa 2427–2428) (Marx et al., 2000), although this
result has been challenged (Masumiya et al., 2003). We did not
observe any significant interaction between FKBP12.6 and the
RyR2 phosphorylation domain. If phosphorylation of S2808
causes FKBP12.6 dissociation, this is therefore more likely to
happen through allosteric changes induced by the phosphoryla-
tion (Blayney et al., 2010).
Another controversial part deals with the identities of the
phosphorylated sites. For example, one study showed that
RyR2 residue S2030, rather than S2808, is the primary target
for PKA (Xiao et al., 2006). Using mass spectrometry, we
observed five phosphorylation sites for PKA and four sites for
CaMKII using purified RyR2 phosphorylation domain. This result
could easily be criticized as being an artifact, because it is theStructure 20, 1201–1211, July 3, 2012 ªresult of a prolonged exposure to the
kinases, and not all target sites may be
accessible within full-length RyRs or,
worse, their complexes with auxiliary
proteins. However, with the exception
of T2876, all other sites have recently
been identified in a large-scale mass
spectrometric analysis of phosphorylated
proteins in several mouse organs (Huttlin
et al., 2010) (Supplemental Informationand http://www.phosphosite.org). Interestingly, all five PKA
sites are embedded in the phosphorylation loop that connects
the two repeats: four of them (S2808, T2810, S2811, and
S2814) are within the flexible portion, and one additional site
(S2797) is in a 310 helix immediately preceding the unstructured
part. Although the functional relevance of these other sites is not
known, the fact that they cluster together implies that there may
be functional redundancy: because they lie at the same face of
the domain, they could have the same effect as phosphorylation
of S2808 or S2814. However, the exact location within the
loop may also be of importance: depending on the proximity to
a crucial interaction point, the precise effect may differ. Interest-
ingly, several peptides in this area have been detected to contain
multiple phosphorylations in vivo (Huttlin et al., 2010), suggesting
that the sequential addition of phosphate groups can give rise
to a tunable response,whereby the interactionwith a neighboring
domain or auxiliary protein could be altered gradually. More
peptides were found to contain two or three phosphorylated
targets than single ones (Huttlin et al., 2010), and the term
‘‘hyperphosphorylation’’ could thus be extended to mean
multiple phosphorylated residues in one domain of a single
RyR. Although all phosphopeptides were detected multiple
times in the large-scale study (Huttlin et al., 2010), it will be inter-
esting to directly measure their relative abundancies.
The clustering of the phosphorylation loop and seven disease
mutations on one particular face suggests that some may be
affecting the same interface in full-length RyR complexes, with
the precise functional effect depending on the nature of the
mutation. A crystal structure of the N-terminal disease hot spot
of RyR1 has shown that most disease mutations affect RyR
domain-domain interfaces (Tung et al., 2010). Is the same true
for the 11 mutations in this domain? Docking of the phosphory-
lation domain into various cryo-EM maps yields a top solution
located in subregion 10. This places one face with mutations at2012 Elsevier Ltd All rights reserved 1207
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Figure 6. RyR2 Phosphorylation Sites
(A) Sequence alignment of the wild-type domains in RyR1, RyR2, and RyR3. The numbering for RyR2 is for the human sequence, which is one amino acid off from
the mouse sequence (e.g., S2807 in mouse is S2808 in human). Phosphorylation sites in RyR2 are color coded: blue, phosphorylated in vitro by CaMKII only; red,
phosphorylated by PKA only; and purple, phosphorylated by both PKA and CaMKII. Targets for diseasemutations in RyR1 are indicated in green. The yellow lines
indicate predicted CaM binding sequences (see also Figure S3). The secondary structure for the RyR1 domain is indicated.
(B) Cartoon representation of the RyR2 phosphorylation domain with phosphorylation sites indicated (human RyR2 numbering). Residues phosphorylated in our
in vitro experiments are labeled with blue spheres (CaMKII) and red spheres (PKA). Additional phosphorylated residues identified in vivo are also indicated (no
spheres).
See also Table S2.
Structure
Structure of the RYR Phosphorylation Hot Spotthe periphery of the intact channel, and the other at an internal
domain-domain interaction (Figure 7B). The docking contrast,
which shows the difference between the top solution and the
next solutions down the ranking, is small, and the position is
therefore not unambiguous.
The docking of the RyR1 N-terminal disease hot spot could be
validated by performing docking experiments with individual
domains, which recapitulated the domain-domain interfaces
observed in the crystal structure (Tung et al., 2010). This test1208 Structure 20, 1201–1211, July 3, 2012 ª2012 Elsevier Ltd All rigcannot be performed on the phosphorylation domain, because
splitting it in two halves yields fragments that are too small to
dock. In addition, the two-fold symmetry also results in an
ambiguity of the orientation. However, experimental restraints
are available: in one cryo-EM study, GFP was fused near RyR2
residue 2801, yielding difference density right next to the phos-
phorylation loop containing the insertion site (Figure 7A) (Meng
et al., 2007). In addition, an antibody against the first half of the
domain yielded a nearby difference density in subregion 6, wellhts reserved
A B
*
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#1 rank
#2 rank
L2785V
L2785V
cavity
E2880K
E2880K
**
T2781 (RYR2)
Y2821 (RYR2)
Figure 7. Cryo-EM Docking
(A) Result of docking the RyR1 phosphorylation domain in the 10.2 A˚ cryo-EM
map of RyR1 in the open state (EMD 1607), using Laplacian filtering im-
plemented in ADP_EM. Results for other maps are shown in Figure S4. For
reference, the RyR1ABC disease hot spot is shown in green. The circles
indicate the position for difference density of GFP, which was inserted at the
asterisk in the phosphorylation loop, and for an antibody against the first half of
the domain (Meng et al., 2007).
(B) Details for two alternative orientations of the domain docked in EMD 1607,
reflecting the two-fold symmetry. Disease mutations in RyR1 are indicated in
black sticks, and the positions of phosphorylation sites not in the flexible loop
are indicated in green sticks. Selected residues are labeled for reference.
Structure
Structure of the RYR Phosphorylation Hot Spotwithin the dimension of an antibody. The location in subregion 10
is therefore compatible with these previous results. The docking
result will need to be confirmed when larger fragments or higher
resolution cryo-EM data become available. The phosphorylation
loop also forms an attractive insertion site to be used for FRET
experiments that could validate or disprove the position and
precise orientation.
Subregion 10 has been shown to undergo large motions,
moving 8 A˚ toward the ER membrane upon channel opening.
In addition, RyR1 has been shown to form intrinsic lattices, and
the nearby subregion 6 has been shown to mediate contacts
with neighboring RyRs (Yin et al., 2005a, 2005b, 2008; Yin and
Lai, 2000). If the proposed position is correct, phosphorylation
and disease mutations in the phosphorylation domain could
thus interfere with the allosteric motions or coupled interactions.
In summary, to our knowledge, we have provided the first
snapshots of a domain in the central region of RyR1, RyR2,
and RyR3. Forming a target for disease mutations and multiple
phosphorylations, this domain must be allosterically coupled to
the channel pore region. Identifying the neighboring domains
will undoubtedly shed more light on its functional mechanisms.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization
Rabbit RyR1 (2734–2940), mouse RyR2 (2699–2904), and human RyR3
(2597–2800) were cloned into the pET28HMT (Lobo and Van Petegem,
2009). The constructs were chosen on the basis of homology with a protein
from Bacteroides tetaiotaomicron VPI-5482 (PDB ID 3NRT; unpublished
structure). Longer constructs for RyR1 were also tested, but these either
resulted in insufficient expression (RyR1 constructs 2713–2983, 2713–3012,
and 2713–3020), or only produced tiny crystals of insufficient quality (RyR1
construct 2713–2940). Mutations were introduced via Quikchange (Strata-
gene). Proteins were expressed and purified as described for other RyR
domains (Lobo and Van Petegem, 2009). Selenomethionine-labeled RyR2Structure 20, 1phosphorylation domain was obtained using the adjusted autoinductionmedia
(Studier, 2005).
Human FKBP12.6 and CaM were cloned in the pET28HT vector, containing
an N-terminal His-tag and a TEV cleavage site. Purification was like that for the
RyR domains, with the following exception for CaM. After cleavage with TEV
protease and an additional PorosMC column, the sample was applied to
a Phenyl-Sepharose HP column (GE Healthcare) equilibrated with 150 mM
KCl, 20 mM HEPES (pH 7.4), and 10 mM CaCl2. The protein was eluted with
the same buffer containing 10 mM EDTA instead of CaCl2. The protein was
applied to a HiLoad Q-Sepharose HP column equilibrated with 20 mM
Na-HEPES (pH 7.4) and 10 mM EDTA and was eluted with a gradient of
20% to 40% of buffer containing an additional 1 M KCl over 14 column
volumes (CV). Molecular weights for all proteins were confirmed by MALDI-
TOF on a Voyager-DE STR (Applied Biosystems).
Protein crystals were grown using the hanging-drop method at 20C.
Wild-type and mutant RyR1 domain (5–10 mg/ml) were crystallized in
0.1 M HEPES (pH 7), 13%–25% (w/v) PEG3350, and 25% (v/v) glycerol.
Surface mutations K2879A and K2775A were introduced to the RyR2 and
RyR3 domains, respectively, to improve crystal quality. SeMet RyR2 phos-
phorylation domain (20–30 mg/ml) crystals were grown in 0.1 M Bicine (pH
9) and 9%–12% (w/v) PEG3350, and RyR3 (20 mg/ml) crystals were grown
in 0.1 M Bicine (pH 9.5) and 1.3–1.4 M (NH4)2SO4. RyR1 phosphorylation
domain crystals were flash-frozen directly, whereas RyR2 and RyR3 domain
crystals were first transferred to a solution supplemented with 25%–30%
glycerol.
Data Collection and Structure Determination
Diffraction data sets were collected at the Canadian Light Source (CLS) beam-
line 08ID-1, Stanford Synchrotron Radiation Lightsource (SSRL) beamline
BL12-2, and the Advanced Photon Source (APS) beamline 23-ID-D-GM/CA
and in-house (Rigaku). Data were processed with XDS (Kabsch, 2010) and
HKL3000 (HKL Research).
Initial phases and a model of the RyR2 phosphorylation domain were calcu-
lated using MAD with AutoSol (Terwilliger et al., 2009). The structure was
refined against a 1.65 A˚ data set using PHENIX (Adams et al., 2010). The
RyR2 domain structure was used as a search model in molecular replacement
by Phaser (McCoy et al., 2007) to solve the RyR1 and RyR3 domain struc-
tures. RyR1 disease mutants were solved via molecular replacement using
the wild-type RyR1 phosphorylation domain model. All models were
completed with iterative cycles of model building in COOT (Emsley and
Cowtan, 2004) and refinement with REFMAC5.5 (Murshudov et al., 1997).
The RyR2 domain structure contains two molecules in the asymmetric unit.
Chain B contains multiple disordered regions, likely underlying the increased
Rwork and Rfree for this structure. All analysis has been performed on chain A.
Statistics are shown in Table 1. All coordinates are available in the PDB
with the following accession numbers: 4ERT (RyR1 domain), 4ETV (RyR2),
4ERV (RyR3), 4ETT (RyR1 E2764K), 4ESU (RyR1 S2776M), and 4ETU (RyR1
R2939S).
Cryo-EM Docking
ADP_EM (Garzo´n et al., 2007) was used to dock the RYR1 phosphorylation
domain into three different RyR1 cryo-EM maps with EMDB entries 1606
(Samso´ et al., 2009), 1607 (Samso´ et al., 2009), and 1275 (Ludtke et al.,
2005), and with the crystal structure blurred to the reported resolutions for
each entry (10.2 A˚, 10.2 A˚, and 9.6 A˚, respectively). Docking was performed
with a bandwidth setting of 32, zero density cut-off, and both with and without
Laplacian filtering.
Fluorescence-Based Thermal Shift Assays
Protein melting curves were measured using fluorescence-based thermal
shift assays (Nettleship et al., 2008). Ten microliters of 1 mg/ml protein was
mixed into a 500 ml solution containing 13 SYPRO orange dye (Invitrogen).
Thermal melts were obtained using a DNA Engine Opticon 2 real-time PCR
machine (Biorad), with the SYBR green filter option. The temperature was
increased from 25C to 95C with 0.5C steps, with the temperature held
constant for 15 sec before data acquisition. Melting temperatures were ob-
tained by taking the transition midpoints.201–1211, July 3, 2012 ª2012 Elsevier Ltd All rights reserved 1209
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Proteins were dialyzed against 150 mM KCl, 10 mM HEPES (pH 7.4), 10 mM
2-mercaptoethanol, and 10 mM CaCl2 at 4
C. Concentrations were deter-
mined using the calculated extinction coefficient at 280 nm in the presence
of 6 M guanidine (Edelhoch, 1967). Titrations consisted of 20–25 injections
of 1.5–2 ml of FKBP12.6 (0.635 mM) or calmodulin (1.2 mM) into the cell con-
taining the RyR2 domain at a 10-fold lower concentration. Experiments were
performed at 25C and a stirring speed of 1000 rpm on an ITC200 instrument
(GE Healthcare). The data were processed using Origin 7.0.
In Vitro Phosphorylation
Phosphorylation reactions were performed at 30C overnight in 50 ml volumes.
The reaction mixture for PKA contained 10 mM HEPES (pH 7.4), 50 mM KCl,
20 mM MgCl2, 0.2 mM ATP, 2 mM 2-mercaptoethanol, 2 mg/ml RyR2, and
50 U PKA (Promega). The mixture for CaMKII contained 10 mM HEPES (pH
7.4), 50 mM KCl, 10 mM MgCl2, 0.5 mM CaCl2, 5 mM CaM, 1 mM ATP,
1 mMDTT, 2 mg/ml RyR2, and 1 mMCaMKII (gift from Dr. Lawrence McIntosh,
University of British Columbia). The unit of PKA is defined as the amount of
enzyme required to incorporate 1 pmol of phosphate into casein in 1 min.
Phosphorylated proteins were trypsinized by adding 20 ml of 2 mg/ml trypsin
(Promega), purified by solid phase extraction on C-18 stage tips and analyzed
using a linear-trapping quadrupole-Orbitrap mass spectrometer (LTQOrbitrap
VELOS; ThermoFisher Scientific) on-line coupled to an Agilent 1100 Series
nanoflow HPLC with nanospray ionization source (ThermoFisher) including
a trap column containing Aqua C-18 beads (Phenomenex), analytical column
with Reprosil-Pur C-18-AQ beads (Dr. Maisch) and a fused silica gold-coated
spray tip.
Sample trapping was done at 5000 nl/min, and analysis was done at
100 nl/min at 6C. Buffer A contained 0.5% acetic acid, and buffer B contained
0.5% acetic acid plus 80% acetonitrile. Gradients were run from 0%–32%
B over 57 min, 32%–40% for 5 min, and 40%–100% over 2 min. Generation
of fragment spectral data andMascot searches were performed with Proteome
Discoverer V.1.2 (ThermoFisher). The searches were against a database of
mouse protein sequences with the following parameters: peptide mass accu-
racy, 10 ppm; fragment mass accuracy, 0.6 Da; and trypsin enzyme specificity
with modifications to carbamidomethyl, methionine oxidation and N-acetyl
peptides, STY phosphorylation, and ESI-TRAP fragment characteristics.
Peptides with IonScores exceeding the individually calculated 99% confidence
limit or the 1% false discover rate were considered as accurately identified.
SUPPLEMENTAL INFORMATION
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